Skip to main content

Table 3 Factors associated with virological suppression of HIV-infected adults on HAART

From: Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy

Variable

 

Virological status

COR (95% CI)

AOR (95% CI)

Virological suppression

No virological suppression

Current age (years)

≤ 30

44

15

1.00

1.00

31–45

137

35

1.33(0.67, 2.67)

2.06 (0.93, 4.53)

> 45

84

8

3.58 (1.4, 9.10)

5.99 (2.12, 16.91)*

Age at enrollment (year)

≤ 25

61

20

1.00

-

26–40

150

35

1.40 (0.75, 2.62)

-

> 40

54

3

5.90 (1.66, 20.96)

-

Duration since ART initiation (year)

1–5

78

19

1.00

 

6–10

123

28

1.17 (0.55 2.48)

-

> 10

64

11

1.37 (0.60, 3.10)

-

Baseline CD4 count (cell/mm3)

< 200

143

33

1.00

-

200–499

94

17

1.27 (0.67, 2.42)

-

> 499

28

8

0.80 (0.34, 1.93)

-

CD4 count at VL testing (cell/mm3)

< 350

70

36

1.00

1.00

350–499

55

11

2.57 (1.20, 5.51)

2.56 (1.14, 5.75)*

> 499

140

11

6.54 (3.14, 13.63)

7.71 (3.48, 17.09)*

Baseline anemic status

Non-anemic

158

28

1.00

-

Anemic

107

30

0.63 (0.35, 1.11)

-

Baseline functional status

Working

228

49

1.00

-

Ambulatory and bedridden

37

9

0.88 (0.40, 1.94)

 

Baseline BMI (kg/m2)

< 18.5

113

26

1.00

-

≥ 18.5

152

32

1.09 (0.61, 1.93)

 

Baseline WHO stage

Stages I and II

77

11

1.00

-

Stage III

154

37

0.59 (0.28, 1.23)

-

Stage IV

34

10

0.48 (0.18, 1.25)

-

Initial regimen

D4T-3TC-based

27

7

1.00

-

AZT-3TC-based

118

25

1.22 (0.48, 3.12)

-

TDF-3TC-based

120

26

1.19 (0.47, 3.04)

-

  1. COR crude odds ratio, AOR adjusted odds ratio, ART antiretroviral therapy, CD4 cluster of differentiation 4, VL viral load, BMI body mass index, WHO World Health Organization, HAART highly active antiretroviral therapy
  2. *Significantly associated at p value < 0.05